Novo Nordisk's Year of Reset
Novo Nordisk cut its outlook, lost Metsera to Pfizer, and saw an Alzheimer's trial fail. Inside the reset — and the amycretin bet on recovery.
The company that defined the GLP-1 era spent the year cutting forecasts, losing directors, and choosing the molecule it will fight with next.
It feels strange to cast the maker of Ozempic and Wegovy as an underdog, yet 2025 humbled Novo Nordisk. The Danish drugmaker that built the modern obesity market found itself on defense — squeezed by competition, tripped by setbacks, and forced into a strategic reset.
The forecast cuts
On November 5, 2025, chief executive Mike Doustdar trimmed the company’s outlook again, citing a slowdown in GLP-1 sales growth. The pressures were structural, not passing. Eli Lilly’s tirzepatide had eaten into Novo’s share. Shortage-era compounded copies had siphoned demand at lower prices. And the pricing deal with the administration, while expanding access, came with concessions that reshaped the revenue math.
For a company whose valuation had soared on the assumption of near-unlimited GLP-1 growth, a second downward revision landed hard with investors.
The setbacks stacked
Trouble arrived on several fronts at once. A boardroom shake-up saw directors depart amid questions about strategy and pace. The company’s ambitious bet that semaglutide could slow Alzheimer’s came back negative when the Evoke trials missed their endpoint. And in the marquee deal of the year, Novo bid aggressively for the obesity developer Metsera, sued, and ultimately lost it to Pfizer — ceding a coveted monthly-dosing platform to a rival that had been absent from the field.
Any one of these would sting. Together, they defined a year of retrenchment for a company accustomed to winning.
The bet on recovery
Every reset needs a thesis, and Novo’s is amycretin — now carrying the generic name zenagamtide. It is the company’s unimolecular peptide, engineered to activate both the GLP-1 and amylin receptors in a single molecule, and it is headed into a broad phase 3 program in 2026 for obesity and type 2 diabetes, in both injectable and oral forms.
The early data are the reason for hope: deep weight loss in obesity trials with no obvious plateau, and strong diabetes results presented in 2026. Analysts frame amycretin bluntly as the asset that could turn Novo’s fortunes — if it can deliver not just a large number but a cleaner tolerability profile than the drugs now crowding the market.
The rebuild beneath the headlines
Novo is not standing still on manufacturing. The company committed roughly $10 billion to expand U.S. production, including domestic manufacturing of its oral semaglutide tablet — a hedge against tariffs and a bet on the durability of demand. It continues to advance CagriSema, its amylin/GLP-1 combination, through the FDA.
A company this large does not vanish in a hard year. It regroups, picks its battles, and chooses its next weapon.
What it means
The lesson of Novo’s year is how quickly dominance erodes in a fast-moving category. Being first built an enormous lead; staying ahead now requires beating rivals on efficacy, tolerability, and convenience simultaneously. The obesity market Novo essentially created has matured into a genuine contest.
For patients, that competition is a gift — more options, better drugs, falling prices. For Novo, it is the challenge of the decade, and amycretin is the answer the company is staking on. The phase 3 readouts will tell whether the reset becomes a comeback.
Frequently asked questions
Why is Novo Nordisk struggling? After creating the modern obesity market, Novo faced a hard 2025: slowing GLP-1 sales growth, share lost to Eli Lilly’s tirzepatide, pricing concessions, a boardroom shake-up, a failed Alzheimer’s trial, and the loss of Metsera to Pfizer.
What is amycretin? Amycretin (generic name zenagamtide) is Novo’s next big bet — a single peptide engineered to activate both the GLP-1 and amylin receptors. It heads into a broad phase 3 program in 2026, in injectable and oral forms, with early data showing deep weight loss and no clear plateau.
Did Novo Nordisk lose Metsera? Yes. Novo bid aggressively and sued, but Pfizer ultimately won Metsera in November 2025, taking its monthly-dosing platform.
Sources
- Novo Nordisk A/S — third-quarter 2025 results and revised financial outlook, November 5, 2025.
- Clinical Trials Arena — coverage of Novo Nordisk’s strategy and amycretin pipeline, November 2025.
- Novo Nordisk A/S — statements on the Metsera bid and its conclusion, 2025.
- Reuters and Bloomberg — reporting on Novo Nordisk’s leadership and outlook, 2025–2026.
- Novo Nordisk A/S — U.S. manufacturing investment announcements, 2025–2026.